Telix Pharmaceuticals Ltd (TLX) ADR EACH REPR SPON

Sell:$18.55Buy:$19.20$0.30 (1.59%)

NASDAQ:0.54%
Prices delayed by at least 15 minutes
Sell:$18.55
Buy:$19.20
Change:$0.30 (1.59%)
Deal now
Prices delayed by at least 15 minutes
Sell:$18.55
Buy:$19.20
Change:$0.30 (1.59%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its segments include commercial, product development, medical technologies, and manufacturing services. Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX101, TLX300, TLX66, TLX66-CDx, and TLX090, among others.

Key people

Christian P. Behrenbruch
Group Chief Executive Officer, Managing Director, Executive Director
Darren Smith
Group Chief Financial Officer
Raphael Ortiz
Chief Executive Officer - APAC and EMEA
Kevin Richardson
Chief Executive Officer, Americas
Darren Patti
Group Chief Operating Officer
Lena Moran - Adams
Group General Counsel
David Cade
Group Chief Medical Officer
James Stonecypher
Group Chief Development Officer
Richard Valeix
Group Chief Commercial Officer
Genevieve Ryan
Company Secretary
H. Kevin Mccann
Non-Executive Independent Chairman of the Board
Mark Nelson
Non-Executive Independent Director
Tiffany P. Olson
Non-Executive Independent Director
Jann Skinner
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Australia
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US87961M1053
  • Market cap
    $0.00
  • Employees
    234
  • Shares in issue
    334.23m
  • Exchange
    Australian Stock Exchange Ltd
  • Index
    ASX All Ordinaries Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.